New Philips Minicare study, page-32

Oslo - that's the great thing about it

Troponin POC is only going to become more popular and competitive and the need for tests to be cheaper, faster and better all play into ADO's sweet spot.

It is the potential for Multiplex capability by using Mixngo where the advantages really come

Think about the surface area of a nanoparticle like valuable real estate

With the traditional method you need to apply more antibody to get the desired result and with this comes a lot of wasted real estate through a wasteland of antibodies lying down on the job like demolished buildings with no yield.

By using Mixngo the antibodies all stand up allowing for better detection and increasing the ability to get more results out of the real estate of the nanoparticles.

Other tests may be fast and sensitive etc - BUT it is the many advantages that Mixngo adds that makes the value proposition so strong

Remember this is only one test in one segment for Anteo

My research on the Global US Life Science company has me just as interested in that potential partnership as well as POC1

Anteo are in a much stronger position than some here realise IMO